A skin rash is an irritated or swollen area of skin and is often a symptom of other medical issues, such as allergies or substance intolerances. Affected areas may redden, itch, cause pain, blister or become raw. Skin rashes can appear quickly or over time, and while most will disappear quickly, some rashes may need long-term treatment if symptoms persist.
Though there are many types of skin rashes, below are some of the most common.
Eczema is a very common skin rash that causes swelling and may involve dryness, itching, scaly patches, infections and blisters. Eczema occurs in newborns, children and adults, and it affects more than 31 million people in the U.S., according to the National Eczema Association. This skin condition can present in many forms, including:
A number of factors contribute to eczema, among them being a persons environment and genetics. In most cases of eczema, an environmental factor triggers an immune response reaction, causing inflammation and eczema symptoms in the skin. This instance is often referred to as a flare up.
Atopic dermatitis is a common form of skin rash and the most common type of eczema. It can affect people of all age groups, from newborns to seniors. This type of skin rash is caused by an overreaction of the immune system to small irritants.
Atopic dermatitis is most common in children, with some reports saying close to 25% of children in the U.S. may have the disease, says Joshua Grosshandler, an Ohio-based dermatologist and fellow of the American Academy of Dermatology. All races can be affected but, in the U.S., there seems to be a higher number of African Americans and Asians than Caucasians.
Dr. Grosshandler explains that atopic dermatitis typically affects those with an atopic diathesis, or a predisposition to seasonal allergies, asthma and food allergies. Atopic dermatitis is a complex disease and is not fully understood.
Research suggests that family history of atopic dermatitis, food allergies, seasonal allergies, asthma, the immune system and environment all likely have a role in causing atopic dermatitis, says Dr. Grosshandler. Atopic dermatitis is a chronic potential lifelong condition and cannot be cured, so the goal of treatment is to control the condition, which includes reducing flares, decreasing symptoms like itch and improving the appearance of the skin.
A variety of medications and skin care routines can be used to help control symptoms, according to Dr. Grosshandler, including:
If youve ever gone hiking only to come home itching and scratching around your ankles, elbows or arms, you may have experienced contact dermatitisirritation or inflammation caused by coming into contact with an allergen or substance like poison ivy, poison oak or another external factor.
Contact dermatitis refers to a group of skin conditions for which the rash is due to direct contact with a causative agent either resulting in the irritation of the skin or an allergic reaction, says Dr. Grosshandler. The two main types are allergic contact dermatitis and irritant contact dermatitis.
Allergic contact dermatitis refers to a skin rash that appears as a delayed allergic reaction. This type of rash may appear one to two days after the skin is exposed to an allergen, such as poison ivy.
Irritant contact dermatitis refers to when skin cells are damaged due to exposure to an irritating substance. These reactions make up nearly 80% of all contact dermatitis cases, according to the National Eczema Association.
Both types of contact dermatitis can develop in anyone, although there are some groups that have a higher risk, such as those with atopic dermatitis, adds Dr. Grosshandler. Some allergens known to cause the condition include nickel, urushiol (the oil in poison ivy, poison oak and poison sumac), fragrance and latex.
Symptoms of contact dermatitis are often itchy, bumpy or flaky skin around the affected area. More severe cases can result in oozing blisters and heavy swelling. Symptoms may also cause disruptions in sleep and day-to-day activities due to discomfort.
To treat contact dermatitis:
Dermatologists may also prescribe steroids to help address itching and accompanying symptoms. In both allergic and irritant cases of contact dermatitis, its important to know and avoid the substance that causes the reaction. For severe allergic reactions, contact your health care provider.
Rosacea is very common in the U.S., with reports of 14 million people affected, according to the American Academy of Dermatology Association. It typically occurs in individuals between 30 and 50 years of age, with women being more likely to be affected than men.
There are four types of rosacea:
Fair-skinned individuals with light hair, light eyes and a Northern European ancestry have the classic background for rosacea, but it can affect those of all skin colors and genetic backgrounds, says Dr. Grosshandler.
The exact cause of rosacea is unknown, but there are multiple theories that involve genetics, environmental factors, vascular changes, inflammation and the immune system, explains Dr. Grosshandler. Sun exposure, for example, can cause the symptoms to intensify. Untreated rosacea tends to worsen over time.
While there isnt a cure for rosacea, there are different approaches to help manage the symptoms. Common rosacea triggers to consider avoiding include:
Medication can also be used to help treat rosacea. Prescription medications [to treat rosacea] include topical metronidazole, topical sodium sulfacetamide sulfur, topical ivermectin, topical azelaic acid, topical tetracycline, topical oxymetazoline, oral tetracycline antibiotics and vascular lasers such as the PDL, says Dr. Grosshandler. He also suggests implementing a consistent skin care routine with sunscreen, gentle cleansers and moisturizers to help manage outbreaks.
Psoriasisa type of rash identified by the itchy, red, scaly texture it creates on skinis thought to be caused by an autoimmune disorder, and it can follow a viral infection such as strep throat. However, the underlying cause of psoriasis is still unknown. If left untreated, psoriasis can worsen and become very painful.
Psoriasis is a common skin condition with approximately 2% of the population affected, says Dr. Grosshandler. Psoriasis can start at any age, but ages 15 to 25 and 50 to 60 are two peaks to see it present.
There are several types of psoriasis, according to the National Institute of Arthritis and Musculoskeletal Diseases.
Much like eczema, experts think psoriasis may be caused by a mixture of geneticspeople with the condition tend to have relatives who also suffer from psoriasisand environmental triggers. Mental health problems, being overweight, infection and some medications are also known triggers of psoriasis.
Medicinal treatment options for psoriasis include topical steroids, topical vitamin D creams, methotrexate (an immune suppressor used to slow the growth and division of cells), retinoids, biologic response monitors (injectable medications used to block, decrease or stop inflammation) Phosphodiesterase 4 (PDE4) inhibitors (used to suppress rapid cell turnover and inflammation) and immunosuppressants, among others.
Phototherapythe use of ultraviolet (UV) light on the affected area of skinis a treatment method typically used when large areas of the body are affected. This treatment can be offered in a doctors office or, if prescribed a proper UV light, at home.
While some rashes are not harmful and can be treated with gentle washing, others can be more severe and spread at rapid rates. If you experience skin rash symptoms, speak with your health care provider to discuss proper diagnosis and treatment.
Find a dermatologist near you
Zocdoc helps you find and book top-rated doctors, on demand. Visit them in their offices, or video chat with them from home. Check out the dermatologists in your area.
Dermatologists Near Me
Follow this link:
Your Guide To Types Of Skin Rashes - Forbes
- Guselkumab Demonstrates Significant Improvement in Psoriasis Symptoms and HRQoL, Reduces Sexual Impairment ... - Dermatology Times - April 18th, 2024 [April 18th, 2024]
- Psoriasis Patients with Arthralgia At Increased Risk of Psoriatic Arthritis Development - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Diagnosing Psoriatic Arthritis for the Dermatologist: Guidance From the Experts - Medscape - April 18th, 2024 [April 18th, 2024]
- Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg - MD Magazine - April 18th, 2024 [April 18th, 2024]
- The Impact of Pediatric Plaque Psoriasis on Children and Caregivers - HMP Global Learning Network - April 18th, 2024 [April 18th, 2024]
- Guselkumab Led to Improvements Over Several Psoriatic Arthritis Disease Domains - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Dual Diagnosing and Managing Psoriasis and Psoriatic Arthritis - The Dermatologist - April 18th, 2024 [April 18th, 2024]
- Etanercept Effective for Psoriasis, Rheumatic Disease Among Patients Extending Treatment After 12-Weeks - MD Magazine - February 9th, 2024 [February 9th, 2024]
- High Response Rates in Psoriasis With Oral IL-23 Inhibitor - Medpage Today - February 9th, 2024 [February 9th, 2024]
- Psoriasis and eczema have complex causes and consequences that researchers are seeking to uncover - Medical Xpress - February 9th, 2024 [February 9th, 2024]
- New Hope in Treatment of Plaque Psoriasis: Study Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- No Difference in Psoriasis Immune Response Despite Switch Between AVT02, Adalimumab - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Oral IL-23 Receptor Antagonist Peptide Effective in PASI Reduction for Psoriasis - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Breakthrough in Psoriasis Treatment: JNJ-77242113 Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from Phase II Trial of Oral Interleukin Inhibitor for Psoriasis Treatment - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from the FRONTIER 1 Trial - An Exploration of JNJ-77242113 in the Treatment of Moderate-to ... - Medriva - February 9th, 2024 [February 9th, 2024]
- Personal Experience with Psoriatic Arthritis and Atopic Dermatitis - Medriva - February 9th, 2024 [February 9th, 2024]
- Rising Cost of Stelara: Impact on Patients and Johnson & Johnson's Market Performance - Medriva - February 9th, 2024 [February 9th, 2024]
- Global Psoriatic Arthritis (PsA) Treatment Market to achieve a remarkable US$ 15.6 Billion by 2028, - PharmiWeb.com - February 9th, 2024 [February 9th, 2024]
- Tremfya potential highlighted by industry analyst GlobalData - The Pharma Letter - May 31st, 2023 [May 31st, 2023]
- Stress Leads to Increased Risk of Depression, Anxiety for Psoriasis ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Janssen Announces Positive Results From Guselkumab Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Early Intervention with Secukinumab May Be Effective for Patients ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Scratching the itch, Lynk Pharmaceuticals trialling ointment for ... - OutSourcing-Pharma.com - May 31st, 2023 [May 31st, 2023]
- Brepocitinib More Efficacious Than Placebo in Long-Term Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- For Patients With Birthmarks, Psychosocial Interventions Improved ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Robert Hariri, MD: Natural Killer Cell Therapy Shows Remarkable ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Nalbuphine ER Tablets Show Promise as Cough Therapy in ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Benefit of Empagliflozin in HFpEF Consistent Regardless of Diuretic ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- selectION reports results from SAD stage of si-544 Phase Ib trial - Clinical Trials Arena - May 31st, 2023 [May 31st, 2023]
- No Link Observed Between Gastrointestinal Tract Surgery and New ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Lynk doses first cohort in Phase Ib trial of psoriasis therapy - Clinical Trials Arena - May 30th, 2023 [May 30th, 2023]
- Metabolic Inflammation Contributes to Depression in Psoriatic Disease - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Encouraging Diversity and Inclusion for Patients With Psoriatic ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- The Weekly Roundup: May 22-26 - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Pediatric Psoriasis Market: A Study of the Industry's Key Applications ... - The Navajo Post - May 30th, 2023 [May 30th, 2023]
- Phototherapy Lamps Market are set to witness a CAGR of 5.8 ... - Digital Journal - May 30th, 2023 [May 30th, 2023]
- Celltrion seeks approval for Stelara biosimilar in EU - The Investor - May 30th, 2023 [May 30th, 2023]
- Peter Marinkovich, MD: FDA Approval of B-VEC Gene Therapy for ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Nick Stucky, MD, Phd: Implications for Media Influence on Minoxidil ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Tildrakizumab Linked With HRQOL Improvement in Psoriasis in a Real-World Setting - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Clinical Utility of Deucravacitinib for the Management of Moderate to ... - Dove Medical Press - May 18th, 2023 [May 18th, 2023]
- Covid-19 and Psoriasis: Is there a link? - Dunya News - May 18th, 2023 [May 18th, 2023]
- Improvement Needed in Study Interventions to Better Skin Self ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data - Marketscreener.com - May 18th, 2023 [May 18th, 2023]
- Adam Friedman, MD: Addressing Disparities in Care for Patients ... - MD Magazine - May 18th, 2023 [May 18th, 2023]
- Early-Infancy Meningitis Infection Linked With Increased Risk of ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- NOVN: Counting Down to PDUFA - Yahoo Finance - May 18th, 2023 [May 18th, 2023]
- Psoriatic Arthritis (PsA) Treatment Market is likely to register CAGR ... - Future Market Insights - May 18th, 2023 [May 18th, 2023]
- New campaign raises awareness of topical steroid withdrawal - Professional Beauty - May 18th, 2023 [May 18th, 2023]
- MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody sonelokimab in... - February 2nd, 2023 [February 2nd, 2023]
- EVELO BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events (form 8-K) -... - February 2nd, 2023 [February 2nd, 2023]
- 12 Ways to Treat Psoriasis at Home - Healthline - January 22nd, 2023 [January 22nd, 2023]
- DTC Advertising Of Prescription Drugs In The U.S. Often Promotes Products With Comparatively Low Therapeutic Value - Forbes - January 19th, 2023 [January 19th, 2023]
- Types of Psoriasis: Pictures, Symptoms and Treatments - Healthline - December 18th, 2022 [December 18th, 2022]
- Psoriasis Pathogenesis and Treatment - PMC - PubMed Central (PMC) - November 23rd, 2022 [November 23rd, 2022]
- Drug-Provoked Psoriasis: Is It Drug Induced or Drug Aggravated? - November 23rd, 2022 [November 23rd, 2022]
- Im a Dermatologist and These 7 Things Could Be Making Your Psoriasis Worse - Well+Good - October 19th, 2022 [October 19th, 2022]
- 'Worst time of the year for me to be covered in scabs': Amber Heard's Alleged Ex Cara Delevingne Revealed Her Psoriasis Struggle Made Kate Moss Scream... - October 19th, 2022 [October 19th, 2022]
- Psoriasis: What It Is, Symptoms, Causes, Types & Treatment - October 17th, 2022 [October 17th, 2022]
- What is psoriasis and which foods ease symptoms? - Evening Standard - October 17th, 2022 [October 17th, 2022]
- Chronic inflammatory diseases: what they are - Emergency Live International - October 17th, 2022 [October 17th, 2022]
- How remote care can deliver a step change in treatment for inflammatory skin conditions - PoliticsHome - October 17th, 2022 [October 17th, 2022]
- Probiotics Supplementation may Improve Symptoms of Hyperuricemia and Gout - Rheumatology Network - October 15th, 2022 [October 15th, 2022]
- Psoriasis Pathogenesis and Treatment - PubMed - October 2nd, 2022 [October 2nd, 2022]
- Best and Worst Drinks for Psoriasis - Everyday Health - October 2nd, 2022 [October 2nd, 2022]
- These Are the 10 Most Common Chronic Skin Conditionsand the Most Important Facts to Know About Them - Parade Magazine - October 2nd, 2022 [October 2nd, 2022]
- Survey Addresses Concerns Regarding Reproductive Healthcare Communication in Women with RA, PsA - Rheumatology Network - October 2nd, 2022 [October 2nd, 2022]
- Psoriasis Types, Symptoms & Causes | NIAMS - September 29th, 2022 [September 29th, 2022]
- What Is Psoriasis And Can It Be Treated? - Forbes - September 29th, 2022 [September 29th, 2022]
- Plaque Psoriasis Treated With Tildrakizumab Shown to be Effective in Real-World Settings - MD Magazine - September 29th, 2022 [September 29th, 2022]
- Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis - Business Wire - September 29th, 2022 [September 29th, 2022]
- 15 Items That Will Make Your Life With Psoriatic Arthritis Easier - BlackDoctor.Org - September 29th, 2022 [September 29th, 2022]
- Types of Psoriasis and Their Effects on the Immune System - Cureus - September 27th, 2022 [September 27th, 2022]
- MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody sonelokimab in patients with active psoriatic arthritis - BioSpace - September 27th, 2022 [September 27th, 2022]
- How diversity and inclusion continues to be incorporated in dermatology - PMLiVE - September 27th, 2022 [September 27th, 2022]
- Arcutis Announces Topline Results From ARRECTOR Pivotal Phase 3 Trial Of Roflumilast Foam 0.3% In Scalp A - Benzinga - September 27th, 2022 [September 27th, 2022]
- Psoriasis Treatment Market Size to Hit USD 51.24 Bn by 2030 - GlobeNewswire - August 15th, 2022 [August 15th, 2022]
- Ventyx Sees Initiation Of Mid-Stage Psoriasis Study In Q4 2022 Following Positive Data From Initial-Stage - Benzinga - August 15th, 2022 [August 15th, 2022]